阿尔茨海默病患者的神经精神症状的性别差异。
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
机构信息
1 Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
出版信息
Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457. doi: 10.1177/1533317518783278. Epub 2018 Jul 3.
Abstract
The aim of this study was to describe sex differences in neuropsychiatric symptoms (NPSs) in patients with Alzheimer's disease (AD). Baseline scores on the Cohen-Mansfield Agitation Inventory, Neurobehavioral Rating Scale-Agitation subscale, and the Neuropsychiatric Inventory from patients with AD enrolled in a multicenter trial of citalopram for the treatment of agitation were analyzed. We found not only that patients with AD having agitation were likely to exhibit many other NPSs but also that the women in this study were more likely to exhibit a broader range of NPS than were the men. These results suggest greater heterogeneity in the clinical presentation of women compared to men, and thus in the potential targets for treatment in these patients. Further characterization of sex differences in NPS can inform future efforts aimed at establishing subtypes of patients for whom various treatment approaches will be most appropriate.
摘要
本研究旨在描述阿尔茨海默病（AD）患者的神经精神症状（NPS）的性别差异。对接受西酞普兰治疗激越的多中心试验中 AD 患者的基线 Cohen-Mansfield 激越量表、神经行为评定量表-激越分量表和神经精神问卷评分进行了分析。我们不仅发现有激越的 AD 患者可能表现出许多其他 NPS，而且研究中的女性比男性更可能表现出更广泛的 NPS。这些结果表明，女性的临床表现比男性更为复杂，因此这些患者的治疗靶点也可能更为复杂。进一步描述 NPS 的性别差异可以为未来确定最适合各种治疗方法的患者亚组的努力提供信息。
相似文献
1
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.阿尔茨海默病患者的神经精神症状的性别差异。
Am J Alzheimers Dis Other Demen. 2018 Nov;33(7):450-457. doi: 10.1177/1533317518783278. Epub 2018 Jul 3.
2
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.西酞普兰对阿尔茨海默病激越的影响：CitAD 随机临床试验。
JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.
3
Citalopram for agitation in Alzheimer's disease: design and methods.西酞普兰治疗阿尔茨海默病激越：设计与方法。
Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.
4
Principal components analysis of agitation outcomes in Alzheimer's disease.阿尔茨海默病中激越结果的主成分分析
J Psychiatr Res. 2016 Aug;79:4-7. doi: 10.1016/j.jpsychires.2016.04.004. Epub 2016 Apr 16.
5
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.西酞普兰治疗阿尔茨海默病痴呆中的激越：遗传影响
J Geriatr Psychiatry Neurol. 2016 Mar;29(2):59-64. doi: 10.1177/0891988715601735. Epub 2015 Aug 23.
6
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.R-西酞普兰和S-西酞普兰浓度对患有痴呆和躁动的老年人的神经精神评分有不同影响。
Br J Clin Pharmacol. 2016 Sep;82(3):784-92. doi: 10.1111/bcp.12997. Epub 2016 Jun 20.
7
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.一项为期九周的对照试验中，安慰剂组阿尔茨海默病患者的激越症状变化。
Int Psychogeriatr. 2015 Dec;27(12):2059-67. doi: 10.1017/S1041610215001106. Epub 2015 Aug 25.
8
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.西酞普兰治疗阿尔茨海默病激越症状的起效时间
Am J Geriatr Psychiatry. 2015 Nov;23(11):1127-33. doi: 10.1016/j.jagp.2015.05.006. Epub 2015 May 19.
9
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.西酞普兰治疗阿尔茨海默病激越（S-CitAD）：一项由研究者发起的、随机、对照、多中心临床试验的方法和设计。
Alzheimers Dement. 2019 Nov;15(11):1427-1436. doi: 10.1016/j.jalz.2019.06.4946. Epub 2019 Oct 3.
10
Antidepressants for agitation and psychosis in dementia.用于治疗痴呆症激越和精神病的抗抑郁药。
Cochrane Database Syst Rev. 2011 Feb 16(2):CD008191. doi: 10.1002/14651858.CD008191.pub2.
引用本文的文献
1
Caregiving burdens of task time and task difficulty among paid and unpaid caregivers of persons living with dementia.痴呆症患者的付费和非付费照料者在任务时间和任务难度方面的照料负担。
Front Public Health. 2025 Jul 9;13:1615187. doi: 10.3389/fpubh.2025.1615187. eCollection 2025.
2
Sex-Specific Adaptations in Alzheimer's Disease and Ischemic Stroke: A Longitudinal Study in Male and Female APP/PS1 Mice.阿尔茨海默病和缺血性中风中的性别特异性适应：对雄性和雌性APP/PS1小鼠的纵向研究
Life (Basel). 2025 Feb 21;15(3):333. doi: 10.3390/life15030333.
3
Specific cognitive impairment predicts the neuropsychiatric symptoms in patient with mild cognitive impairment.特定认知障碍可预测轻度认知障碍患者的神经精神症状。
Aging Clin Exp Res. 2025 Mar 1;37(1):60. doi: 10.1007/s40520-025-02952-6.
4
Behavioral and Psychological Symptoms of Dementia and Mortality Risk Among People With Cognitive Impairment: An 8-year Longitudinal Study From the NCGG-STORIES.认知障碍人群的痴呆行为和心理症状与死亡风险：来自 NCGG-STORIES 的 8 年纵向研究。
J Epidemiol. 2024 Nov 5;34(11):543-552. doi: 10.2188/jea.JE20230343. Epub 2024 Sep 30.
5
Cognitive Performance and Incident Alzheimer's Dementia in Men Versus Women.男性与女性的认知表现与阿尔茨海默病发病风险。
J Prev Alzheimers Dis. 2024;11(1):162-170. doi: 10.14283/jpad.2023.90.
6
A brainstem to circadian system circuit links Tau pathology to sundowning-related disturbances in an Alzheimer's disease mouse model.一个脑干到生物钟系统的回路将 Tau 病理学与阿尔茨海默病小鼠模型中与日落相关的紊乱联系起来。
Nat Commun. 2023 Aug 18;14(1):5027. doi: 10.1038/s41467-023-40546-w.
7
Metabolic changes in the plasma of mild Alzheimer's disease patients treated with Hachimijiogan.八味地黄丸治疗轻度阿尔茨海默病患者血浆中的代谢变化。
Front Pharmacol. 2023 Jun 12;14:1203349. doi: 10.3389/fphar.2023.1203349. eCollection 2023.
8
White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases.脑白质高信号和皮质变薄与神经退行性疾病和脑血管病的神经精神症状有关。
Alzheimers Res Ther. 2023 Jun 20;15(1):114. doi: 10.1186/s13195-023-01257-y.
9
Malnutrition and neuropsychiatric symptoms in dementia: the Cache County Dementia Progression Study.痴呆患者的营养不良与神经精神症状：Cache 县痴呆进展研究。
Int Psychogeriatr. 2023 Nov;35(11):653-663. doi: 10.1017/S1041610223000467. Epub 2023 May 29.
10
Neuropsychiatric Symptoms as Indicators of Fall Risk in Geriatric Inpatients.神经精神症状是老年住院患者跌倒风险的指标。
Medicina (Kaunas). 2023 May 5;59(5):887. doi: 10.3390/medicina59050887.
本文引用的文献
1
The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review.神经精神问卷特定项目与痴呆患者照料者负担的关系：系统评价。
Int J Geriatr Psychiatry. 2017 Jul;32(7):703-717. doi: 10.1002/gps.4704. Epub 2017 Mar 20.
2
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.西酞普兰对阿尔茨海默病激越的影响：CitAD 随机临床试验。
JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.
3
Gender differences in clinical manifestations and outcomes among hospitalized patients with behavioral and psychological symptoms of dementia.住院患者痴呆行为和心理症状的临床表现和结局的性别差异。
J Clin Psychiatry. 2012 Dec;73(12):1548-54. doi: 10.4088/JCP.11m07614.
4
Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia.血管性痴呆认知和神经精神表现的阶段特异性性别差异。
Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):433-8. doi: 10.1177/1533317512454712.
5
Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients.阿尔茨海默病和血管性痴呆患者的神经精神症状和功能状态。
Curr Alzheimer Res. 2012 Jul;9(6):759-71. doi: 10.2174/156720512801322582.
6
Correlates of agitation and depression in nursing home residents with dementia.养老院痴呆患者激越与抑郁的相关因素。
Int Psychogeriatr. 2012 Nov;24(11):1779-89. doi: 10.1017/S104161021200066X. Epub 2012 May 17.
7
Citalopram for agitation in Alzheimer's disease: design and methods.西酞普兰治疗阿尔茨海默病激越：设计与方法。
Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.
8
Gender differences in antidepressant drug response.抗抑郁药反应的性别差异。
Int Rev Psychiatry. 2010;22(5):485-500. doi: 10.3109/09540261.2010.496448.
9
Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease.阿尔茨海默病初诊未治疗患者大样本中神经精神症状和综合征。
Am J Geriatr Psychiatry. 2010 Nov;18(11):1026-35. doi: 10.1097/JGP.0b013e3181d6b68d.
10
Predictors of neuropsychiatric symptoms in nursing home patients: influence of gender and dementia severity.养老院患者神经精神症状的预测因素：性别和痴呆严重程度的影响。
Int J Geriatr Psychiatry. 2009 Oct;24(10):1079-86. doi: 10.1002/gps.2225.
Zotero 插件